泓博医药：现阶段DiOrion平台药物研发服务的直接收入占整体营收比重较小

Core Viewpoint - The company, Hongbo Pharmaceutical, announced that its stock price experienced an abnormal fluctuation, with a cumulative increase of over 30% in closing prices over two consecutive trading days [1] Group 1: Company Operations - The company conducted a self-examination and confirmed that there are no undisclosed significant matters regarding its operations as of the announcement date [1] - The company's current operations are normal, and there have been no significant changes [1] Group 2: Revenue Impact - The direct revenue from the DiOrion platform's drug development services constitutes a small proportion of the company's overall revenue, thus not significantly impacting the overall business performance [1]